130 related articles for article (PubMed ID: 12501127)
41. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G; Cahn P; Chokephaibulkit K; Fourie J; Karatzios C; Dincq S; Opsomer M; Kakuda TN; Nijs S; Tambuyzer L; Tomaka FL;
HIV Med; 2014 Oct; 15(9):513-24. PubMed ID: 24589294
[TBL] [Abstract][Full Text] [Related]
42. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Buckheit RW; Russell JD; Xu ZQ; Flavin M
Antivir Chem Chemother; 2000 Sep; 11(5):321-7. PubMed ID: 11142630
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
44. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
Matthews RP; Patel M; Barrett SE; Haspeslagh L; Reynders T; Zhang S; Rottey S; Goodey A; Vargo RC; Grobler JA; Stoch SA; Iwamoto M
Nat Med; 2021 Oct; 27(10):1712-1717. PubMed ID: 34608329
[TBL] [Abstract][Full Text] [Related]
45. In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
Xu ZQ; Buckheit RW; Stup TL; Flavin MT; Khilevich A; Rizzo JD; Lin L; Zembower DE
Bioorg Med Chem Lett; 1998 Aug; 8(16):2179-84. PubMed ID: 9873509
[TBL] [Abstract][Full Text] [Related]
46. GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
Arasteh K; Wood R; Müller M; Prince W; Cass L; Moore KH; Dallow N; Jones A; Klein A; Burt V; Kleim JP
HIV Clin Trials; 2001; 2(4):307-16. PubMed ID: 11590533
[TBL] [Abstract][Full Text] [Related]
47. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
[TBL] [Abstract][Full Text] [Related]
49. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
50. In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model.
Xu ZQ; Hollingshead MG; Borgel S; Elder C; Khilevich A; Flavin MT
Bioorg Med Chem Lett; 1999 Jan; 9(2):133-8. PubMed ID: 10021914
[TBL] [Abstract][Full Text] [Related]
51. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.
Zhou XJ; Garner RC; Nicholson S; Kissling CJ; Mayers D
J Clin Pharmacol; 2009 Dec; 49(12):1408-16. PubMed ID: 19776293
[TBL] [Abstract][Full Text] [Related]
52. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
53. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
[TBL] [Abstract][Full Text] [Related]
54. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
55. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Zhang Z; Xu W; Koh YH; Shim JH; Girardet JL; Yeh LT; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2007 Feb; 51(2):429-37. PubMed ID: 17116677
[TBL] [Abstract][Full Text] [Related]
56. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
[TBL] [Abstract][Full Text] [Related]
58. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
[TBL] [Abstract][Full Text] [Related]
59. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
60. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
